# First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

> **NCT06603844** · PHASE1,PHASE2 · RECRUITING · sponsor: **Corbus Pharmaceuticals Inc.** · enrollment: 156 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** CRB-601 monoclonal antibody
- **DRUG:** Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT06603844
- **Lead sponsor:** Corbus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2026-11-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 156 (ESTIMATED)
- **Last updated:** 2025-06-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603844, "First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06603844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*